Abstract
Lesion size of PCV. Tsujikawa, et al. Page 2 Polypoidal choroidal vasculopathy (PCV) was first described as a new clinical entity with a unique form of choroidal vascular abnormality, [1] [2] [3] and is characterized by a branching vascular network that terminates in polypoidal lesions seen by indocyanine green angiography. 4 Initially, vascular components of PCV are reported to be seen predominantly in a peripapillary location, 5 but macular PCV 6, 7 and peripheral PCV 5, 8 5 have since been reported. Yannuzzi and associates 9 expanded the clinical spectrum of this disease and established the current understanding of PCV. Today, macular PCV is more common in Asian populations and seems to be the condition most clinically significant. 7, 10, 11 To date, however, the pathogenesis of PCV is not fully understood, and it is still controversial as to whether or not it originates from an abnormality of the inner 10 choroidal vessels or if it is a variant of choroidal neovascularization (CNV).
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PCV is accompanied often by recurrent serosanguineous detachments of the retinal pigment epithelium and neurosensory retina, and sometimes results in massive hemorrhagic complications with a sudden loss of vision. 13, 14 While the extent of visual disturbance in PCV varies, it is generally thought that the visual prognosis of PCV is 15 better than that of exudative age-related macular degeneration (AMD). 11, 12 In a previous report by Uyama and associates, 11 about half of the patients with PCV had a favorable visual outcome (better than 20/30) after being followed-up for more than 2 years. In PCV, other vision-threatening complications, such as type 2 CNV, disciform scar, or cystoid macular edema, are reported to be uncommon.
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Clinically, the size of the vascular lesions in PCV varies. 15 We sometimes see cases of PCV with a large lesion that show a poor response to the treatment and show progression of the lesion, resulting in poor visual prognosis. Tateiwa and associates 16 reported that PCV with a large vascular network that extends beyond the vascular arcade is not uncommon, so we might speculate that vascular lesions of originally small 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Lesion size of PCV. Tsujikawa, et al. Page 3 this type of progression. 17 PCV cases with a small lesion often show minimal exudative change and no progression of the lesion, and can maintain good visual function for a long time. 18 Even with an exudative change, small PCV often show a favorable response to treatment. 19 Okubo and associates 18 reported that a reddish-orange nodule alone, or that multiple reddish-orange nodules with a small subretinal hemorrhage, is a sign of a 5 potentially benign clinical course, so the clinical course of small and large PCV may be different.
In order to study the progression of vascular lesions in PCV, it is essential to perform repeated indocyanine green angiography, 4 because most vascular lesions of PCV are located beneath the retinal pigment epithelium. [1] [2] [3] So far, however, there is little 10 information on the long-term observation of the vascular components of PCV. 15 In the study described herein, we investigated progression of the vascular lesion of PCV using indocyanine green angiography and visual prognosis of affected eyes. Based on our findings, we report a new classification of PCV and the expected complications and visual prognosis of these two types of PCV.
15
PATIENTS AND METHODS
For this observational case study, we reviewed retrospectively the medical records of 88 consecutive patients (88 eyes) with symptomatic PCV who initially visited the Macula
Service of the Department of Ophthalmology at Kyoto University Hospital between
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January 2004 and October 2007, and who had been examined with both fluorescein and indocyanine green angiography for more than 2 years after their initial visit. When both eyes were diagnosed as having PCV, one eye was selected randomly for inclusion in the current study.
The diagnosis of PCV was based on indocyanine green angiography, which shows 25 a branching vascular network that terminates in polypoidal swelling. The polypoidal   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Lesion size of PCV. Tsujikawa, et al. Page 4 lesion can be a single polyp or a cluster of multiple polyps. In most cases, the reddish-orange nodule that had been seen by the ophthalmoscopic examination corresponded to the polypoidal lesion. Eyes with other macular abnormalities (i.e., AMD, pathologic myopia, idiopathic CNV, presumed ocular histoplasmosis, angioid streaks, and other secondary CNV) were excluded from the current study. Eyes that were treated 5 previously with focal laser photocoagulation, photodynamic therapy (PDT), vitrectomy, radiation therapy, or anti-vascular endothelial growth factor (VEGF) therapy were also excluded from the present study.
At the initial visit, all patients underwent a comprehensive ophthalmologic examination, including measurement of best-corrected visual acuity (VA), determination 10 of intraocular pressure, indirect ophthalmoscopy, slitlamp biomicroscopy with a contact lens, and optical coherence tomography (OCT). After fundus photographs were taken, fluorescein and indocyanine green angiography were performed on each patient using a confocal laser scanning system (HRA-2, Heidelberg Engineering, Dossenheim, Germany). In all patients, VA measurement and OCT examination were performed at 15 each follow-up visit. At follow-up visits, angiography was performed if necessary, although all patients in the current study were examined with angiography several times during their follow-up. In the study described herein, the angiograms obtained at the initial visit were compared with the final angiograms.
In the current study, greatest linear dimension and area of the lesion were 20 determined based on the indocyanine green angiography, using the software built into the HRA-2 machine. Greatest linear dimension included the entire PCV vascular lesion, including polypoidal lesion, branching vascular network vessels, and any type 2 CNV.
The area of the vascular lesion was measured manually with the software that came with the HRA-2. The pigment epithelial detachment, without underlying vascular components,
25
was not included in measurement of the greatest linear dimension and area of the lesion. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Lesion size of PCV. Tsujikawa, et al. Page 5 In the current study, one optic-disc area (DA) is equal to 2.54 mm 2 , on the basis of one optic disc diameter being equal to 1.8 mm. Based on the area of the lesion at the initial visit, we classified the eyes into either the smaller PCV group (baseline area of lesion < 1 DA) or the larger PCV group (baseline area of lesion > 1 DA) in order to compare the clinical course of the two groups.
5
We also compared the initial OCT measurement and VA with values obtained at the final visit. To compare the difference in VA, VA measured with a Landolt chart was converted to a logarithm of the minimal angle of resolution (logMAR). Using OCT images, we performed two measurements (foveal thickness, and thickness of the neurosensory retina in the fovea) with a caliper that was built into the software of the OCT machine.
10
Foveal thickness was defined as the distance between the vitreoretinal interface and the retinal pigment epithelium; thickness of the neurosensory retina was defined as the distance between the vitreoretinal interface and the tip the outer segment of the inner and outer segments of the photoreceptors.
We genotyped the major AMD and PCV-associated SNP, rs10490924 (A69S), of 15 ARMS2. Genomic DNA was prepared from leukocytes of peripheral blood using a DNA extraction kit (QuickGene-610L, Fujifilm, Minato, Tokyo, Japan). The SNPs were genotyped using Taqman SNP assays with the ABI PRISM 7700 system (Applied Biosystems, Foster City, California) according to the manufacturer's instructions.
Statistical analysis was performed using software designed for this purpose
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(StatView, version 5.0; SAS Institute, Cary, North Carolina). A P value of less than 0.05 was considered to be statistically significant.
RESULTS
In the current study, 88 eyes of 88 patients (60 men and 28 women) with PCV, ranging in 25 age from 50 to 86 years (70.4 ± 7.5 years), were examined. The follow-up period ranged from 29 to 61 months (46.4 ± 8.6 months), and duration from the initial angiogram to the last ranged from 24 to 60 months (39.3 ± 9.4 months). All patients were examined with fluorescein and indocyanine green angiography repeatedly during follow-up, ranging from 2 to 11 times (4.9 ± 2.0 times). Table 1 shows the characteristics of patients eligible for inclusion in this study. The mean baseline VA (logMAR) was 0.37 ± 0.34. The mean 5 initial area of the lesion and greatest linear dimension was 7.75 ± 9.78 mm 2 and 3412 ± 1647μm, respectively. Figure 1 shows the relationship between area of the lesion, greatest linear dimension, foveal thickness, and VA at initial visit and final examination.
Initial area of the lesion (R = 0.801, P < .0001) and initial greatest linear dimension (R = 0.805, P < .0001) showed a close correlation with final measurements. 10.55 mm 2 in the larger PCV group. There were no significant differences in gender, age, or duration of symptoms between groups (P = .5971, P = .3257, and P = .6484, respectively). In addition, there were no differences in the foveal thickness (P = .4628) or thickness of the neurosensory retina in the fovea (P = .4204) at the initial visit. However, the initial VA was significantly better in eyes with smaller PCV (0.24 ± 0.39) than in eyes 20 with larger PCV (0.42 ± 0.35, P = .0383).
During the follow-up period, 64 eyes were treated initially with PDT, and 9 were treated initially with anti-VEGF therapy. In spite of these treatments, some eyes with larger PCV showed extension of the vascular component with an exudative change. The mean area of the lesion in larger PCV progressed significantly from 9.79 ± 10.55 mm 2 to 25 16.27± 14.19 mm 2 at the final examination (P < .0001) (Figure 3) . Furthermore, VA in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 , respectively, which were significantly less than those of the larger PCV (P = .0429 and P = .0002, respectively). In addition, eyes with the smaller PCV showed no decrease in VA (-0.05 ± 0.36, P = .5492), and maintained initial VA to the final visit; mean changes in VA were significantly better in smaller PCV than were those in larger 10 PCV (P = .0015). Table 2 shows the ocular manifestations and complications seen during follow-up in eyes with smaller or larger PCV. Of the 88 eyes included, seven (7.6%) showed suprachoroidal hemorrhage and eight (8.7%) showed vitreous hemorrhage ( Figure 5 ), all of which were seen in eyes with larger PCV; no eyes with smaller PCV showed 15 severe complications (P = .1111 and P = .0868). Indeed, in eyes with smaller PCV, even the relatively small amount of subretinal hemorrhage noted (> 1 DA) was seen less frequently than in eyes with larger PCV (P = .0157). In addition, other ocular manifestations associated with severe visual disturbance were seen more often in eyes with larger PCV. Type 2 CNV, subretinal fibrosis, and cystoid macular edema were seen 20 more frequently in eyes with larger PCV (P = .0030, P = .0533, and P = .0266). Of the 88 eyes included in this study, 41 (46.6%) showed a serosanguineous pigment epithelial detachment (area > 1 DA). Again, a pigment epithelial detachment was seen more frequently in eyes with larger PCV than in those with smaller PCV (P = .0096). Of the 88 eyes of our patients, eight (8.7%) showed a tear of the retinal pigment epithelium. All of 25 these occurred in eyes with larger PCV; no eyes with smaller PCV showed a tear (P = .0868).
We were able to examine the DNA of 76 of the 88 patients. Table 3 increased the likelihood for the larger PCV group by 5.0-fold, and heterozygosity for the at-risk genotype (GT) increased the likelihood for this same group by 1.5-fold.
DISCUSSION
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Based on the initial area of the vascular lesion, we defined smaller PCV as those with a baseline area of < 1 DA. The remaining PCV, in which the baseline area was > 1 DA, were defined as larger PCV. There were no significant differences in age or duration of symptoms between these two groups. The larger PCV did, however, often show progression of the vascular lesions, which in many instances showed an exudative 15 change. In larger PCV, poor initial VA was even further lessened in spite of the treatment.
In contrast, most eyes diagnosed as having smaller PCV showed only minimal progression of the lesion, and limited exudative change. Furthermore, smaller PCV lesions rarely progressed to extensive PCV lesions. Most eyes with smaller PCV had good initial VA, and maintained their good VA throughout the follow-up period.
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In addition, severe complications such as suprachoroidal hemorrhage, vitreous hemorrhage, and a tear of the retinal pigment epithelium were seen only in eyes with larger PCV; no eyes with smaller PCV showed these severe complications. Furthermore, type 2 CNV and subfoveal fibrosis was seen more frequently in larger PCV. From these findings, we believe that the ocular manifestations, complications, and visual prognosis 25 of smaller PCV are distinct from those of larger PCV. Okubo and associates 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 65 When the vascular lesion is located far from the fovea, visual prognosis tends to be good. 5 Uyama and associates 11 reported two patterns of fundus manifestation of PCV, exudative and hemorrhagic. However, they reported also that 36% of the cases had 25 altered their pattern of manifestation during follow-up. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 65 14 The branching vascular network, which only rarely disappeared with treatment, tended to extend over time. 35 It is thought that progression of PCV is slower than that of 25 exudative AMD. 9 Yannuzzi and associates 9 reported that the branching vascular network 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 
In PCV patients, Sakurada and associates 40 reported a difference in the genotypic frequency at this site between eyes with and without vitreous hemorrhage, with the frequency of the T allele being significantly greater in the vitreous hemorrhage group than that in the non-vitreous hemorrhage group. 40 In another report, Sakurada and associates 46 reported that this genotype is not associated with lesion composition or size 25 as seen by indocyanine green angiography. However, they did indicate that the T allele 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Lesion size of PCV. Tsujikawa, et al. Page 12 at this SNP is associated with the exudative activity of polypoidal lesions. 46 While further studies are necessary to elucidate the contribution of this SNP to the progression of the vascular lesion, this SNP appears to be associated with the occurrence of PCV itself and with activity of the vascular lesions.
Limitations of the current study are its retrospective nature and the various 5 treatment regimens used. Our patents received primarily PDT or anti-VEGF therapy.
25-29
Because recent studies have suggested that PDT in combination with anti-VEGF therapy may be the most promising treatment of PCV, it is possible that our patients did not receive the most effective treatment. 4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 
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One disc area (DA) is estimated as 2.54 mm 2 on the basis of one optic disc diameter being 1.8 mm.
Based on the area of the lesion at the initial visit, polypoidal choroidal vasculopathy (PCV) eyes were divided into smaller PCV (area of lesion < 1 DA) and larger PCV (area of lesion > 1 DA). ; this is based on one optic disc diameter being 1.8 mm. Based on the area of the lesion at the initial visit, polypoidal choroidal vasculopathy (PCV) eyes were divided into smaller PCV (area of lesion < 1 DA) and larger PCV (area of lesion > 1 DA). 
